Drugs in the Pipeline Xeljanz Under FDA Review for Psoriatic Arthritis Publish Date May 5, 2017 An anticipated Prescription Drug User Fee Act (PDUFA) action date of December 2017 has been set by the FDA for both Xeljanz sNDAs.
